article
New research improves the safety and effectiveness of ADC cancer treatments
Learn how the University at Buffalo is pioneering safer, more effective ADC therapies.
List view / Grid view
cytotoxicity
article
A label-free imaging technique for drug evaluation at single‑cell level
This article provides a brief overview of the technical and conceptual advantages of Raman spectroscopy, a label-free imaging technique that is being increasingly used for the purpose of drug evaluation.
news
Assay to reveal anti-tumour T-cell cytotoxicity via flow cytometry developed
A simple co-culture assay that can assess anti-tumour T-cell cytotoxicity via luminescence and flow cytometry has been created.
article
Antibodies allow for a targeted approach to cancer therapy
Cancer can be an immovable beast, tenacious in its numerous mechanisms to thrive and grow. However, the healthcare industry has an ever-expanding arsenal of therapies designed to thwart it, with variable levels of success. Nikki Withers speaks to Dr Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs at the Cancer…
news
Increasing ion channel function in cancer T cells could be new immunotherapy
Researchers have found that there is less calmodulin binding to ion channels in the T cells from cancer patients, presenting a new immunotherapeutic target.
news
High-throughput screening used to discover new class of antibiotics
Researchers have used a high-throughput screening method to test over 125,000 molecules and identify a new class of antibiotics.
article
Screening In-Depth Focus 2018
This In-Depth Focus reviews the history of cancer treatments, looks at improving the translation of disease biology though phenomics, and considers how to enhance cell bioprocessing through cell-based combinatorial culture.
news
SMi’s 9th annual RNA Therapeutics conference will take place in just 2 weeks!
Presenting issues and real-life examples within the RNA space, SMi welcome insights and discussions into new technologies for single-stranded RNA, epigenetics to develop first-in class drugs in oncology, patenting RNA Therapeutics and exploring the latest developments in delivery systems, including Exosomes and Nanocomplexes. Read on for your exclusive discount to…
news
Hear from Janssen and Antikor Biopharma at SMi’s ADC Conference, April 2018
SMi's ADC conference will be bringing a global presence from Pfizer, Genentech, Ablynx, Spirogen, Seattle Genetics, Medimmune, Antikor Biopharma, Heidelberg Pharma and more...
whitepaper
Application note: Fc-Receptor binding in ADCC assays utilising LANCE Ultra Technology – characterisation of hIGs and FcγRIIIa
In this application note, PerkinElmer demonstrates the ease and utility of using LANCE® Ultra, a homogeneous assay format, for determining binding profiles of therapeutic monoclonal antibodies to FcγRs.
article
Q&A: Implementing ADCC assays in QC: when donor variability isn’t an option
DiscoverX recently introduced the single donor-derived KILR CD16 Effector Cells to ensure assay reproducibility for screening, characterisation, and QC lot release of antibody drugs.
news
BTSA1 causes cancer to self-destruct without affecting healthy cells
Scientists have discovered a compound that causes cancer cells to self-destruct while sparing healthy cells...
webinar
Implementing ADCC assays in QC: When donor variability isn’t an option
6 October 2017 | By DiscoverX Corporation
In this webinar, we discussed how two qualification studies on KILR CD16 Effector Cells demonstrated accuracy and precision in different assays formats.
whitepaper
Application note: A high-throughput, radioactivity-free assay for cell-mediated cytotoxicity
In this application note, IntelliCyt Corporation demonstrate a fast, efficient, radioactivity-free CMC assay with low sample input requirements, enabling miniaturisation to 384-well plates, using the iQue® Screener...
article
How NIH’s $30 million research fund will help find HIV cure
20 July 2016 | By Niamh Louise Marriott, Digital Content Producer
The NIH recently awarded $30 million to advance science towards a cure for HIV. Drug Target Review caught up with the Wistar Institute‘s Dr. Luis Montaner, co-leader of the BEAT-HIV project...